WhaleCreep

Casdin Capital, LLC 13F holdings, Q3 2023

Hedge fundSEC filingsCompare with another fundHoldings as of 2023-09-30, filed 2023-11-14

Casdin Capital, LLC disclosed 38 US equity positions worth $896.6m in its Q3 2023 13F filing. Its largest position is SRPT at 13.7% of the reported book, followed by BLFS and EQRX INC. Versus Q2 2023 it opened 2 new positions, added to 7, reduced 11 and exited 5.

$897m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
38
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
13.7%
Largest position
The largest single position as a share of the reported equity book.
70.4%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
15
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2023: 2 new, 7 added, 11 reduced, 5 exited

38 rows
SRPT SAREPTA THERAPEUTICS INCHealthcare13.7%$122m1.01m−0.5%held
BLFS BIOLIFE SOLUTIONS INCHealthcare12.0%$107m7.78m+0.8%added
EQRX INC no ticker–9.8%$87.8m39.53m0.0%held
GPCR STRUCTURE THERAPEUTICS INCHealthcare6.9%$62.0m1.26m+26%added
RLAY RELAY THERAPEUTICS INCHealthcare6.5%$58.2m6.92m+15%added
RVMD REVOLUTION MEDICINES INCHealthcare5.6%$50.1m1.81m0.0%held
VERVE THERAPEUTICS INC no ticker–4.4%$39.2m2.95m+25%added
NTLA INTELLIA THERAPEUTICS INCHealthcare4.2%$37.3m1.18m−7.6%reduced
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare4.0%$35.4m200,000−29%reduced
EXK EXACT SCIENCES CORPBasic Materials3.5%$31.3m459,450−8.1%reduced
SLGCUSD SOMALOGIC INC–3.4%$30.1m12.60m0.0%held
PLRX PLIANT THERAPEUTICS INCHealthcare3.1%$27.3m1.58m−7.2%reduced
DNLI DENALI THERAPEUTICS INCHealthcare3.0%$26.8m1.30m0.0%held
MRTXEUR MIRATI THERAPEUTICS INC–2.4%$21.7m498,427+1993%added
2655787D BLUEPRINT MEDICINES CORP–2.1%$18.7m371,378−40%reduced
TNYA TENAYA THERAPEUTICS INCHealthcare1.8%$16.3m6.38m0.0%held
TNGX TANGO THERAPEUTICS INCHealthcare1.6%$14.7m1.31m+31%added
BEAM BEAM THERAPEUTICS INCHealthcare1.5%$13.7m570,0000.0%held
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare1.5%$13.2m1.03m−3.4%reduced
WGS GENEDX HOLDINGS CORPHealthcare1.3%$11.3m3.10m0.0%held
ABCL ABCELLERA BIOLOGICS INCHealthcare1.2%$10.9m2.36m−6.3%reduced
PACB PACIFIC BIOSCIENCES CALIF INHealthcare1.0%$8.6m1.04m–new
RNAGBP AVIDITY BIOSCIENCES INC–0.9%$8.0m1.25m+47%added
TSVT* 2SEVENTY BIO INC–0.9%$7.9m2.02m0.0%held
IPSC CENTURY THERAPEUTICS INCHealthcare0.7%$6.4m3.21m0.0%held
MXCT MAXCYTE INCHealthcare0.7%$5.9m1.89m−60%reduced
FATE FATE THERAPEUTICS INCHealthcare0.5%$4.3m2.05m0.0%held
PRME PRIME MEDICINE INC–0.4%$3.5m367,1750.0%held
LAB STANDARD BIOTOOLS INCHealthcare0.4%$3.5m1.20m0.0%held
ILMN ILLUMINA INCHealthcare0.4%$3.4m25,000−84%reduced
SANA SANA BIOTECHNOLOGY INCHealthcare0.3%$2.9m750,0000.0%held
GLUE MONTE ROSA THERAPEUTICS INCHealthcare0.3%$2.4m510,8820.0%held
ABSI ABSCI CORPORATIONHealthcare0.1%$1.3m973,260−29%reduced
EXAIEUR EXSCIENTIA PLC–0.1%$967k213,9000.0%held
CDXS CODEXIS INCHealthcare0.06%$567k300,000–new
SINGULAR GENOMICS SYSTEMS IN no ticker–0.06%$504k1.32m−1.6%reduced
LIANY LIANBIO–0.03%$308k206,4150.0%held
KRON1USD KRONOS BIO INC–0.02%$161k123,8390.0%held

Exited since Q2 2023

5 rows
CTLTEUR CATALENT INC2.7%$31.2m
TWST TWIST BIOSCIENCE CORP0.8%$9.2m
INCY INCYTE CORP0.4%$4.8m
SG7 SAGE THERAPEUTICS INC0.4%$4.2m
SCLXUSD SCILEX HOLDING CO0.01%$131k

Sector mix

  • Healthcare72.1%
  • Unclassified24.4%
  • Basic Materials3.5%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters